Aceragen (Aceragen) Days Sales Outstanding : 118.42 (As of Mar. 2023)

View and export this data going back to 1996. Start your Free Trial

What is Aceragen Days Sales Outstanding?

Aceragen's average Accounts Receivable for the three months ended in Mar. 2023 was $3.21 Mil. Aceragen's Revenue for the three months ended in Mar. 2023 was $2.47 Mil. Hence, Aceragen's Days Sales Outstanding for the three months ended in Mar. 2023 was 118.42.

The historical rank and industry rank for Aceragen's Days Sales Outstanding or its related term are showing as below:

ACGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 141.33 Med: 315.86 Max: 315.86
Current: 141.33

During the past 13 years, Aceragen's highest Days Sales Outstanding was 315.86. The lowest was 141.33. And the median was 315.86.

ACGN's Days Sales Outstanding is not ranked
in the Biotechnology industry.
Industry Median: 71.83 vs ACGN: 141.33

Aceragen's Days Sales Outstanding increased from Mar. 2022 (0.00) to Mar. 2023 (118.42).

Warning Sign:

If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.

Aceragen Days Sales Outstanding Historical Data

The historical data trend for Aceragen's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aceragen Days Sales Outstanding Chart

Aceragen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Days Sales Outstanding

Get a 7-Day Free Trial

315.90

Aceragen Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Days Sales Outstanding	Get a 7-Day Free Trial															-	-	3,657.45	58.51	118.42

Competitive Comparison of Aceragen's Days Sales Outstanding

For the Biotechnology subindustry, Aceragen's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aceragen's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aceragen's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Aceragen's Days Sales Outstanding falls into.

Aceragen Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Aceragen's Days Sales Outstanding for the fiscal year that ended in Dec. 2022 is calculated as

	Days Sales Outstanding (A: Dec. 2022 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2021 )	+	Accounts Receivable (A: Dec. 2022 ))	/	count )	/	Revenue (A: Dec. 2022 )	*	Days in Period
=	( (0	+	4.208)	/	1 )	/	4.862	*	365
=	4.208					/	4.862	*	365
=	315.90

Aceragen's Days Sales Outstanding for the quarter that ended in Mar. 2023 is calculated as:

	Days Sales Outstanding (Q: Mar. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Mar. 2023 ))	/	count )	/	Revenue (A: Mar. 2023 )	*	Days in Period
=	( (4.208	+	2.203)	/	2 )	/	2.47	*	365 / 4
=	3.2055					/	2.47	*	365 / 4
=	118.42

Aceragen (NAS:ACGN) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Aceragen Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Aceragen's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Aceragen (Aceragen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aceragen Inc (NAS:ACGN) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

505 Eagleview Boulevard, Suite 212, Exton, PA, USA, 19341

Website

https://www.aceragen.com

Aceragen Inc is a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases. The company portfolio includes late-stage programs based on well-established biological principles that are developing to be inventive therapeutics capable of addressing the unmet medical needs of individuals living with rare diseases.

Executives

Vincent Milano	director, officer: President & CEO	C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Maxine Gowen	director
Pillar Invest Corp	director, 10 percent owner	C/O PILLAR INVEST OFFSHORE SAL, STARCO CENTER, BLOC B FL3, OMAR DAOUK ST, BEIRUT M8 2020-3313
Atul Chopra	10 percent owner	C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
John Clayton Taylor	director, officer: Chief Executive Officer	C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
Carl N Kraus	officer: Chief Medical Officer	C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
Andrew R Jordan	officer: Chief Strategy Officer	C/O GUILFORD PHARMACEUTICALS INC, 6611 TIBUTARY ST., BALTIMORE MD 21224
Daniel Salain	officer: Chief Operating Officer	C/O GRAYBUG VISION, INC., 275 SHORELINE DRIVE, SUITE 450, REDWOOD CITY CA 94065
Ronald J Wooten	director
Nq Pof V Gp, Ltd.	director, other: See Remarks	4208 SIX FORKS ROAD, SUITE 920, RALEIGH NC 27609
Novaquest Co-investment Fund Xv, L.p.	director, other: See Remarks	4208 SIX FORKS ROAD, SUITE 920, RALEIGH NC 27609
John J. Kirby	officer: V.P. of Finance, PFO & PAO	C/O IDERA PHARMACEUTICALS, INC., 505 EAGLEVIEW BLVD., SUITE 212, EXTON PA 19341
Michael R Dougherty	director	C/O ADOLOR CORP, 700 PENNSYLVANIA DR, EXTON PA 19341
Elizabeth Ann Tarka	officer: Chief Medical Officer	111 WAVERLY CIRCLE, PHOENIXVILLE PA 19460
Bryant David Lim	officer: SVP & General Counsel	C/O IDERA PHARMACEUTICALS, INC., 505 EAGLEVIEW BLVD., SUITE 212, EXTON PA 19341